F. Bădulescu *, V. Voicu **, Mariana Aciu ***, LM. Pop *, Nelly Cherciu *
* Prof. Dr. F. Bădulescu, șef Clinică Oncologie, UMF Craiova
** Prof. Dr. Victor Voicu, șef disciplină Toxicologie Clinică, UMF București
*** Fam. Mariana Aciu, șef lucrări Fac. Farmacie, UMF Craiova
* Dr. L. M. Pop, asistent Oncologie, UMF Craiova
* Dr. Nelly Cherciu, rezident Oncologie, UMF Craiova
Abstract
The aim of study is a comparative evaluation of dinatrium pamidronate (Aredia®) and of the calcitonine (Miacalcic®) treatment effects in patients with advanced malignant neoplasia, with symptomatical lithic bone metastasis. The study has comprised two groups: the first enrolling 10 patients treated with pamidronate, and the second group enrolling 10 patients too, treated with calcitonine. After the first dose of every drug it was noted an improving of the bone pain intensity and of the mobility, but with an evident effect after 6-8 weeks of Miacalcci ® treatment and 4-6 weeks of Aredia® treatment. Also, it was noted a lowering of the alcaline phosphatase value with 38% rate in Aredia® treated group and 27% in Miacalcic® treated group. lmagistic, only at 2 patients it was observed the lesion remission (the lowering of calcification measure), 16 patients presenting the disease stability or even the lithic lesion progression (2 cases).